Spots Global Cancer Trial Database for 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Official Title: A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer

Study ID: NCT04216134

Conditions

Biochemically Recurrent Prostate Carcinoma

Interventions

Gallium Ga 68-labeled PSMA-11

Positron Emission Tomography

Study Description

Brief Summary: This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for 'prostate specific membrane antigen'. Diagnostic procedures, such as 68GA-PSMA-11 PET imaging, may help measure a patient's response to earlier treatment, and may help plan the best treatment for prostate cancer.

Detailed Description: PRIMARY OBJECTIVE: I. To provide clinical access to and assess the safety of the investigational agent Gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA-11) positron emission tomography (PET) at City of Hope National Medical Center for patients co-enrolled on Institutional Review Board (IRB) 18517 treatment trial. OUTLINE: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) over less than 1 minute, and then undergo PET over 60 minutes. After completion of study, patients are followed up at 1-3 days, and then at 3 weeks.